Melanoma

Medical Care Technologies Inc. (OTC PINK:MDCE) Accelerates Growth Strategy with Strategic Capital Raise Following Launch of AI Consumer Platform

MESA, AZ / ACCESS Newswire / April 23, 2026 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced a strategic...

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing...

Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026

TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and significantly attenuated tumor progression in aged gastric microenvironment in preclinical models...

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to...

Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting

Medical Care Technologies (OTC PINK:MDCE) Reaffirms Commitment to AI-Driven Medical Innovation Following Successful Consumer App Launch

Company leverages proven AI deployment capabilities to accelerate clinical-grade healthcare solutions. MESA, AZ / ACCESS Newswire / April 16, 2026...

Phio Pharmaceuticals Announces “Nobel Prize Winning Science Takes on Skin Cancer” in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026

Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR. Todd...

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the...

FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity

Preclinical models demonstrate potential to restore thymic function lost with aging reducing susceptibility to cancer, autoimmune diseases, infections, and reduced...

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

error: Content is protected !!